289 related articles for article (PubMed ID: 36446798)
21. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
[No Abstract] [Full Text] [Related]
22. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
Zhu Z; Liu M; Zhang H; Zheng H; Li J
Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
[TBL] [Abstract][Full Text] [Related]
23. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax.
Yang Y; Shu Y; Chen G; Yin Y; Li F; Li J
PLoS One; 2022; 17(12):e0278725. PubMed ID: 36477747
[TBL] [Abstract][Full Text] [Related]
24. Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system.
Cheng Q; Shi X; Zhao Y; Zou S; Sun M
Expert Opin Drug Saf; 2024 May; 23(5):637-648. PubMed ID: 38564277
[TBL] [Abstract][Full Text] [Related]
25. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
Cui Z; Cheng F; Wang L; Zou F; Pan R; Tian Y; Zhang X; She J; Zhang Y; Yang X
Front Pharmacol; 2023; 14():1259908. PubMed ID: 37954852
[No Abstract] [Full Text] [Related]
26. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
[No Abstract] [Full Text] [Related]
27. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
28. Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022.
Du Y; Zhu J; Guo Z; Wang Z; Wang Y; Hu M; Zhang L; Yang Y; Wang J; Huang Y; Huang P; Chen M; Chen B; Yang C
Expert Rev Clin Pharmacol; 2024; 17(2):189-201. PubMed ID: 38269492
[TBL] [Abstract][Full Text] [Related]
29. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
30. Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system.
Zhao Y; Jiang H; Xue L; Zhou M; Zhao X; Liu F; Jiang S; Huang J; Meng L
Int J Clin Pharm; 2024 Apr; 46(2):480-487. PubMed ID: 38245663
[TBL] [Abstract][Full Text] [Related]
31. Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.
Shu Y; Ding Y; Liu L; Zhang Q
CNS Neurosci Ther; 2023 Sep; 29(9):2705-2716. PubMed ID: 37032639
[TBL] [Abstract][Full Text] [Related]
32. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
33. Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study.
Yuan T; Li F; Hou Y; Guo H
Front Pharmacol; 2023; 14():1266890. PubMed ID: 38074150
[No Abstract] [Full Text] [Related]
34. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
Li Z; Guo C; Liu X; Qiu Z; Zhang R
Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
[No Abstract] [Full Text] [Related]
35. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
36. A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam.
He W; Wang Y; Chen K
Front Pharmacol; 2024; 15():1278442. PubMed ID: 38327980
[No Abstract] [Full Text] [Related]
37. A real-world disproportionality analysis of the FDA adverse event reporting system events for ibuprofen.
Du Y; Guo Z; Xu B; Yang Y; Hu M; Hu Y; Yang Y; Zhang M; Wang Z; Guo X; Huang Y; Zhu J; Zhang W; Yang C
Expert Opin Drug Saf; 2024 May; ():1-11. PubMed ID: 38686498
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS.
Sun Y; Xu T; Zhu S; Xu H
Expert Opin Drug Saf; 2024 Mar; 23(3):305-311. PubMed ID: 37795911
[TBL] [Abstract][Full Text] [Related]
39. Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system.
Zhang Y; Ran L; Liang Y; Zhang Y; An Z
Front Pharmacol; 2023; 14():1194545. PubMed ID: 37554985
[No Abstract] [Full Text] [Related]
40. A Real-World Pharmacovigilance Study of Ceftazidime/Avibactam: Data Mining of the Food and Drug Administration Adverse Event Reporting System Database.
Yao H; Wang Y; Peng Y; Huang Z; Gan G; Wang Z
J Clin Pharmacol; 2024 Feb; ():. PubMed ID: 38375685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]